$1.11 EPS Expected for GATX (GATX), Resmed (RMD) Has 0.99 Sentiment

June 19, 2017 - By Winifred Garcia

ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing , chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. The company has market cap of $11.07 billion. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. It has a 32.86 P/E ratio. The Company’s cloud software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes.

Analysts expect GATX Corporation (NYSE:GATX) to report $1.11 EPS on July, 20.They anticipate $0.38 EPS change or 25.50% from last quarter’s $1.49 EPS. GATX’s profit would be $43.79M giving it 14.61 P/E if the $1.11 EPS is correct. After having $1.44 EPS previously, GATX Corporation’s analysts see -22.92% EPS growth. The stock increased 0.28% or $0.18 on June 16, reaching $64.89. About shares traded. GATX Corporation (NYSE:GATX) has risen 36.88% since June 19, 2016 and is uptrending. It has outperformed by 20.18% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 20 insider sales for $15.39 million activity.

The stock increased 1.22% or $0.93 on June 16, reaching $77.1. About shares traded. ResMed Inc. (RMD) has risen 20.34% since June 19, 2016 and is uptrending. It has outperformed by 3.64% the S&P500.

Analysts await ResMed Inc. (NYSE:RMD) to report earnings on July, 27. They expect $0.75 earnings per share, up 1.35% or $0.01 from last year’s $0.74 per share. RMD’s profit will be $107.68M for 25.70 P/E if the $0.75 EPS becomes a reality. After $0.71 actual earnings per share reported by ResMed Inc. for the previous quarter, Wall Street now forecasts 5.63% EPS growth.

Ratings analysis reveals 0 of ResMed’s analysts are positive. Out of 3 Wall Street analysts rating ResMed, 0 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $59.0 while the high is $64.0. The stock’s average target of $61.50 is -20.23% below today’s ($77.1) share price. RMD was included in 3 notes of analysts from August 23, 2016. On Tuesday, August 23 the stock rating was downgraded by Jefferies to “Underperform”. Canaccord Genuity maintained it with “Hold” rating and $59.0 target in Tuesday, January 24 report. The rating was initiated by JP Morgan on Tuesday, October 4 with “Neutral”.

Blue Jay Capital Management Llc holds 5.43% of its portfolio in ResMed Inc. for 145,000 shares. Matthews International Capital Management Llc owns 1.10 million shares or 3.51% of their US portfolio. Moreover, American Capital Management Inc has 3.22% invested in the company for 673,085 shares. The Connecticut-based Halsey Associates Inc Ct has invested 3.22% in the stock. Professional Advisory Services Inc, a Florida-based fund reported 204,275 shares.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>